BACKGROUND: Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with decreased risk of several malignancies. NSAIDs may prevent cancer development by blocking the cyclooxygenase-catalyzed synthesis of proinflammatory prostaglandins. Aspirin may also protect against Hodgkin's lymphoma by inhibiting transcription factor nuclear factor kappaB (NF-kappaB), which is necessary for immune function and the survival of Hodgkin's lymphoma cells. We examined the association between regular analgesic use and the risk of Hodgkin's lymphoma. METHODS: A population-based case-control study of 565 case patients with Hodgkin's lymphoma and 679 control subjects was conducted in the metropolitan area of Boston, Massachusetts, and in the state of Connecticut. Participants reported their average use of aspirin, non-aspirin NSAIDs, and acetaminophen over the previous 5 years. Regular analgesic use was defined as consumption of at least two tablets per week on average over the preceding 5 years; non-regular use was defined as consumption of fewer than two tablets per week. RESULTS: The risk of Hodgkin's lymphoma associated with regular aspirin use was statistically significantly lower (odds ratio [OR] = 0.60, 95% confidence interval [CI] = 0.42 to 0.85) than that associated with non-regular aspirin use. The risk was not associated with use of other non-aspirin NSAIDs (OR = 0.97, 95% CI = 0.73 to 1.30). However, the risk associated with regular acetaminophen use was statistically significantly higher (OR = 1.72, 95% CI = 1.29 to 2.31) than that associated with non-regular use. CONCLUSION: The inverse association between aspirin, but not other NSAIDs, and Hodgkin's lymphoma suggests that NF-kappaB signaling may play a key role in Hodgkin's lymphoma pathogenesis.
BACKGROUND: Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with decreased risk of several malignancies. NSAIDs may prevent cancer development by blocking the cyclooxygenase-catalyzed synthesis of proinflammatory prostaglandins. Aspirin may also protect against Hodgkin's lymphoma by inhibiting transcription factor nuclear factor kappaB (NF-kappaB), which is necessary for immune function and the survival of Hodgkin's lymphoma cells. We examined the association between regular analgesic use and the risk of Hodgkin's lymphoma. METHODS: A population-based case-control study of 565 case patients with Hodgkin's lymphoma and 679 control subjects was conducted in the metropolitan area of Boston, Massachusetts, and in the state of Connecticut. Participants reported their average use of aspirin, non-aspirin NSAIDs, and acetaminophen over the previous 5 years. Regular analgesic use was defined as consumption of at least two tablets per week on average over the preceding 5 years; non-regular use was defined as consumption of fewer than two tablets per week. RESULTS: The risk of Hodgkin's lymphoma associated with regular aspirin use was statistically significantly lower (odds ratio [OR] = 0.60, 95% confidence interval [CI] = 0.42 to 0.85) than that associated with non-regular aspirin use. The risk was not associated with use of other non-aspirin NSAIDs (OR = 0.97, 95% CI = 0.73 to 1.30). However, the risk associated with regular acetaminophen use was statistically significantly higher (OR = 1.72, 95% CI = 1.29 to 2.31) than that associated with non-regular use. CONCLUSION: The inverse association between aspirin, but not other NSAIDs, and Hodgkin's lymphoma suggests that NF-kappaB signaling may play a key role in Hodgkin's lymphoma pathogenesis.
Authors: Alain Monnereau; Sally L Glaser; Clayton W Schupp; Karin Ekström Smedby; Silvia de Sanjosé; Eleanor Kane; Mads Melbye; Lenka Forétova; Marc Maynadié; Anthony Staines; Nikolaus Becker; Alexandra Nieters; Paul Brennan; Paolo Boffetta; Pierluigi Cocco; Ingrid Glimelius; Jacqueline Clavel; Henrik Hjalgrim; Ellen T Chang Journal: Blood Date: 2013-09-09 Impact factor: 22.113
Authors: Julie L Kasperzyk; Ellen T Chang; Brenda M Birmann; Peter Kraft; Tongzhang Zheng; Nancy E Mueller Journal: Am J Epidemiol Date: 2011-08-01 Impact factor: 4.897
Authors: Ellen T Chang; Deirdre P Cronin-Fenton; Søren Friis; Henrik Hjalgrim; Henrik Toft Sørensen; Lars Pedersen Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-01 Impact factor: 4.254
Authors: Yongshun Gao; Qian Li; Bryan A Bassig; Ellen T Chang; Min Dai; Qin Qin; Yawei Zhang; Tongzhang Zheng Journal: Cancer Causes Control Date: 2013-01-12 Impact factor: 2.506
Authors: Qian Li; Ellen T Chang; Bryan A Bassig; Min Dai; Qin Qin; Yongshun Gao; Yawei Zhang; Tongzhang Zheng Journal: Cancer Causes Control Date: 2012-12-04 Impact factor: 2.506